Fatty Liver Disease Drugs Market Size, Share & Industry Analysis, By Product (Rezdiffra (Resmetirom), Wegovy (Semaglutide), and Others), By Drug Class (THR-beta Agonist, GLP-1 Receptor Agonist, and Others), By Route of Administration (Oral and Parenteral), By Distribution Channel (Hospital Pharmacies, Retail Pharmacies & Drug Stores, and Specialty Pharmacies & Others), and Regional Forecast, 2026-2034

Last Updated: April 24, 2026 | Format: PDF | Report ID: FBI116006

We will customize the report to meet your research goals, helping you gain a competitive edge, and make informed decisions.

Schedule a 30 minutes session to understand our consulting capabilities – SCHEDULE NOW

Table of Content

Introduction
1. Research Scope
2. Market Segmentation
3. Research Methodology
4. Definitions and Assumptions
Executive Summary
Market Dynamics
1. Market Drivers
2. Market Restraints
3. Market Opportunities
4. Market Trends
Key Insights
1. Pipeline Analysis, By Key Players
2. Key Industry Developments (Mergers, Acquisitions, Partnerships, etc.)
3. New Product Launches, By Key Players
4. Regulatory Scenario, By Key Countries/Regions
Global Fatty Liver Disease Drugs Market Analysis, Insights and Forecast, 2021-2034
1. Market Analysis, Insights and Forecast – By Product
  1. Rezdiffra (Resmetirom)
  2. Wegovy (Semaglutide)
  3. Others
2. Market Analysis, Insights and Forecast – By Drug Class
  1. THR-beta Agonist
  2. GLP-1 Receptor Agonist
  3. Others
3. Market Analysis, Insights and Forecast – By Route of Administration
  1. Oral
  2. Parenteral
4. Market Analysis, Insights and Forecast – By Distribution Channel
  1. Hospital Pharmacies
  2. Retail Pharmacies & Drug Stores
  3. Specialty Pharmacies & Others
5. Market Analysis, Insights and Forecast – Region
  1. North America
  2. Europe
  3. Asia Pacific
  4. Rest of the World
North America Fatty Liver Disease Drugs Market Analysis, Insights and Forecast, 2021-2034
1. Market Analysis, Insights and Forecast – By Product
  1. Rezdiffra (Resmetirom)
  2. Wegovy (Semaglutide)
  3. Others
2. Market Analysis, Insights and Forecast – By Drug Class
  1. THR-beta Agonist
  2. GLP-1 Receptor Agonist
  3. Others
3. Market Analysis, Insights and Forecast – By Route of Administration
  1. Oral
  2. Parenteral
4. Market Analysis, Insights and Forecast – By Distribution Channel
  1. Hospital Pharmacies
  2. Retail Pharmacies & Drug Stores
  3. Specialty Pharmacies & Others
5. Market Analysis, Insights and Forecast – By Country
  1. U.S.
  2. Canada
Europe Fatty Liver Disease Drugs Market Analysis, Insights and Forecast, 2021-2034
1. Market Analysis, Insights and Forecast – By Product
  1. Rezdiffra (Resmetirom)
  2. Wegovy (Semaglutide)
  3. Others
2. Market Analysis, Insights and Forecast – By Drug Class
  1. THR-beta Agonist
  2. GLP-1 Receptor Agonist
  3. Others
3. Market Analysis, Insights and Forecast – By Route of Administration
  1. Oral
  2. Parenteral
4. Market Analysis, Insights and Forecast – By Distribution Channel
  1. Hospital Pharmacies
  2. Retail Pharmacies & Drug Stores
  3. Specialty Pharmacies & Others
5. Market Analysis, Insights and Forecast – By Country/ Sub-Region
  1. U.K.
  2. Germany
  3. France
  4. Italy
  5. Spain
  6. Rest of Europe
Asia Pacific Fatty Liver Disease Drugs Market Analysis, Insights and Forecast, 2021-2034
1. Market Analysis, Insights and Forecast – By Product
  1. Rezdiffra (Resmetirom)
  2. Wegovy (Semaglutide)
  3. Others
2. Market Analysis, Insights and Forecast – By Drug Class
  1. THR-beta Agonist
  2. GLP-1 Receptor Agonist
  3. Others
3. Market Analysis, Insights and Forecast – By Route of Administration
  1. Oral
  2. Parenteral
4. Market Analysis, Insights and Forecast – By Distribution Channel
  1. Hospital Pharmacies
  2. Retail Pharmacies & Drug Stores
  3. Specialty Pharmacies & Others
5. Market Analysis, Insights and Forecast – By Country/ Sub-Region
  1. China
  2. Japan
  3. India
  4. Australia
  5. Rest of Asia Pacific
Rest of the World Fatty Liver Disease Drugs Market Analysis, Insights and Forecast, 2021-2034
1. Market Analysis, Insights and Forecast – By Product
  1. Rezdiffra (Resmetirom)
  2. Wegovy (Semaglutide)
  3. Others
2. Market Analysis, Insights and Forecast – By Drug Class
  1. THR-beta Agonist
  2. GLP-1 Receptor Agonist
  3. Others
3. Market Analysis, Insights and Forecast – By Route of Administration
  1. Oral
  2. Parenteral
4. Market Analysis, Insights and Forecast – By Distribution Channel
  1. Hospital Pharmacies
  2. Retail Pharmacies & Drug Stores
  3. Specialty Pharmacies & Others
Competitive Analysis
1. Global Market Share Analysis (2025)
2. Company Profiles (Overview, Products, SWOT analysis, Recent developments, strategies, financials (based on availability)
  1. Madrigal Pharmaceuticals, Inc.
  2. Novo Nordisk
  3. F. Hoffmann-La Roche Ltd (89bio, Inc.)
  4. Inventiva
  5. Boehringer Ingelheim International GmbH
  6. Viking Therapeutics
  7. Altimmune

Introduction
1. Research Scope
2. Market Segmentation
3. Research Methodology
4. Definitions and Assumptions
Executive Summary
Market Dynamics
1. Market Drivers
2. Market Restraints
3. Market Opportunities
4. Market Trends
Key Insights
1. Pipeline Analysis, By Key Players
2. Key Industry Developments (Mergers, Acquisitions, Partnerships, etc.)
3. New Product Launches, By Key Players
4. Regulatory Scenario, By Key Countries/Regions
Global Fatty Liver Disease Drugs Market Analysis, Insights and Forecast, 2021-2034
1. Market Analysis, Insights and Forecast – By Product
  1. Rezdiffra (Resmetirom)
  2. Wegovy (Semaglutide)
  3. Others
2. Market Analysis, Insights and Forecast – By Drug Class
  1. THR-beta Agonist
  2. GLP-1 Receptor Agonist
  3. Others
3. Market Analysis, Insights and Forecast – By Route of Administration
  1. Oral
  2. Parenteral
4. Market Analysis, Insights and Forecast – By Distribution Channel
  1. Hospital Pharmacies
  2. Retail Pharmacies & Drug Stores
  3. Specialty Pharmacies & Others
5. Market Analysis, Insights and Forecast – Region
  1. North America
  2. Europe
  3. Asia Pacific
  4. Rest of the World
North America Fatty Liver Disease Drugs Market Analysis, Insights and Forecast, 2021-2034
1. Market Analysis, Insights and Forecast – By Product
  1. Rezdiffra (Resmetirom)
  2. Wegovy (Semaglutide)
  3. Others
2. Market Analysis, Insights and Forecast – By Drug Class
  1. THR-beta Agonist
  2. GLP-1 Receptor Agonist
  3. Others
3. Market Analysis, Insights and Forecast – By Route of Administration
  1. Oral
  2. Parenteral
4. Market Analysis, Insights and Forecast – By Distribution Channel
  1. Hospital Pharmacies
  2. Retail Pharmacies & Drug Stores
  3. Specialty Pharmacies & Others
5. Market Analysis, Insights and Forecast – By Country
  1. U.S.
  2. Canada
Europe Fatty Liver Disease Drugs Market Analysis, Insights and Forecast, 2021-2034
1. Market Analysis, Insights and Forecast – By Product
  1. Rezdiffra (Resmetirom)
  2. Wegovy (Semaglutide)
  3. Others
2. Market Analysis, Insights and Forecast – By Drug Class
  1. THR-beta Agonist
  2. GLP-1 Receptor Agonist
  3. Others
3. Market Analysis, Insights and Forecast – By Route of Administration
  1. Oral
  2. Parenteral
4. Market Analysis, Insights and Forecast – By Distribution Channel
  1. Hospital Pharmacies
  2. Retail Pharmacies & Drug Stores
  3. Specialty Pharmacies & Others
5. Market Analysis, Insights and Forecast – By Country/ Sub-Region
  1. U.K.
  2. Germany
  3. France
  4. Italy
  5. Spain
  6. Rest of Europe
Asia Pacific Fatty Liver Disease Drugs Market Analysis, Insights and Forecast, 2021-2034
1. Market Analysis, Insights and Forecast – By Product
  1. Rezdiffra (Resmetirom)
  2. Wegovy (Semaglutide)
  3. Others
2. Market Analysis, Insights and Forecast – By Drug Class
  1. THR-beta Agonist
  2. GLP-1 Receptor Agonist
  3. Others
3. Market Analysis, Insights and Forecast – By Route of Administration
  1. Oral
  2. Parenteral
4. Market Analysis, Insights and Forecast – By Distribution Channel
  1. Hospital Pharmacies
  2. Retail Pharmacies & Drug Stores
  3. Specialty Pharmacies & Others
5. Market Analysis, Insights and Forecast – By Country/ Sub-Region
  1. China
  2. Japan
  3. India
  4. Australia
  5. Rest of Asia Pacific
Rest of the World Fatty Liver Disease Drugs Market Analysis, Insights and Forecast, 2021-2034
1. Market Analysis, Insights and Forecast – By Product
  1. Rezdiffra (Resmetirom)
  2. Wegovy (Semaglutide)
  3. Others
2. Market Analysis, Insights and Forecast – By Drug Class
  1. THR-beta Agonist
  2. GLP-1 Receptor Agonist
  3. Others
3. Market Analysis, Insights and Forecast – By Route of Administration
  1. Oral
  2. Parenteral
4. Market Analysis, Insights and Forecast – By Distribution Channel
  1. Hospital Pharmacies
  2. Retail Pharmacies & Drug Stores
  3. Specialty Pharmacies & Others
Competitive Analysis
1. Global Market Share Analysis (2025)
2. Company Profiles (Overview, Products, SWOT analysis, Recent developments, strategies, financials (based on availability)
  1. Madrigal Pharmaceuticals, Inc.
  2. Novo Nordisk
  3. F. Hoffmann-La Roche Ltd (89bio, Inc.)
  4. Inventiva
  5. Boehringer Ingelheim International GmbH
  6. Viking Therapeutics
  7. Altimmune

Read Less

List of Figures

Figure 1: Global Fatty Liver Disease Drugs Market Revenue Breakdown (USD million, %) By Region, 2025 & 2034

Figure 2: Global Fatty Liver Disease Drugs Market Value Share (%), By Product, 2025 & 2034

Figure 3: Global Fatty Liver Disease Drugs Market Value Share (%), By Drug Class, 2025 & 2034

Figure 4: Global Fatty Liver Disease Drugs Market Value Share (%), By Route of Administration, 2025 & 2034

Figure 5: Global Fatty Liver Disease Drugs Market Value Share (%), By Distribution Channel, 2025 & 2034

Figure 6: Global Fatty Liver Disease Drugs Market Value Share (%), By Region, 2025 & 2034

Figure 7: North America Fatty Liver Disease Drugs Market Value (USD million), By Product, 2025 & 2034

Figure 8: North America Fatty Liver Disease Drugs Market Value Share (%), By Product, 2025

Figure 9: North America Fatty Liver Disease Drugs Market Value (USD million), By Drug Class, 2025 & 2034

Figure 10: North America Fatty Liver Disease Drugs Market Value Share (%), By Drug Class, 2025

Figure 11: North America Fatty Liver Disease Drugs Market Value (USD million), By Route of Administration, 2025 & 2034

Figure 12: North America Fatty Liver Disease Drugs Market Value Share (%), By Route of Administration, 2025

Figure 13: North America Fatty Liver Disease Drugs Market Value (USD million), By Distribution Channel, 2025 & 2034

Figure 14: North America Fatty Liver Disease Drugs Market Value Share (%), By Distribution Channel, 2025

Figure 15: North America Fatty Liver Disease Drugs Market Value (USD million), by Country, 2025 & 2034

Figure 16: North America Fatty Liver Disease Drugs Market Value Share (%), by Country, 2025

Figure 17: Europe Fatty Liver Disease Drugs Market Value (USD million), By Product, 2025 & 2034

Figure 18: Europe Fatty Liver Disease Drugs Market Value Share (%), By Product, 2025

Figure 19: Europe Fatty Liver Disease Drugs Market Value (USD million), By Drug Class, 2025 & 2034

Figure 20: Europe Fatty Liver Disease Drugs Market Value Share (%), By Drug Class, 2025

Figure 21: Europe Fatty Liver Disease Drugs Market Value (USD million), By Route of Administration, 2025 & 2034

Figure 22: Europe Fatty Liver Disease Drugs Market Value Share (%), By Route of Administration, 2025

Figure 23: Europe Fatty Liver Disease Drugs Market Value (USD million), By Distribution Channel, 2025 & 2034

Figure 24: Europe Fatty Liver Disease Drugs Market Value Share (%), By Distribution Channel, 2025

Figure 25: Europe Fatty Liver Disease Drugs Market Value (USD million), by Country/ Sub-region, 2025 & 2034

Figure 26: Europe Fatty Liver Disease Drugs Market Value Share (%), by Country/ Sub-region, 2025

Figure 27: Asia Pacific Fatty Liver Disease Drugs Market Value (USD million), By Product, 2025 & 2034

Figure 28: Asia Pacific Fatty Liver Disease Drugs Market Value Share (%), By Product, 2025

Figure 29: Asia Pacific Fatty Liver Disease Drugs Market Value (USD million), By Drug Class, 2025 & 2034

Figure 30: Asia Pacific Fatty Liver Disease Drugs Market Value Share (%), By Drug Class, 2025

Figure 31: Asia Pacific Fatty Liver Disease Drugs Market Value (USD million), By Route of Administration, 2025 & 2034

Figure 32: Asia Pacific Fatty Liver Disease Drugs Market Value Share (%), By Route of Administration, 2025

Figure 33: Asia Pacific Fatty Liver Disease Drugs Market Value (USD million), By Distribution Channel, 2025 & 2034

Figure 34: Asia Pacific Fatty Liver Disease Drugs Market Value Share (%), By Distribution Channel, 2025

Figure 35: Asia Pacific Fatty Liver Disease Drugs Market Value (USD million), by Country/ Sub-region, 2025 & 2034

Figure 36: Asia Pacific Fatty Liver Disease Drugs Market Value Share (%), by Country/ Sub-region, 2025

Figure 37: Rest of the World Fatty Liver Disease Drugs Market Value (USD million), By Product, 2025 & 2034

Figure 38: Rest of the World Fatty Liver Disease Drugs Market Value Share (%), By Product, 2025

Figure 39: Rest of the World Fatty Liver Disease Drugs Market Value (USD million), By Drug Class, 2025 & 2034

Figure 40: Rest of the World Fatty Liver Disease Drugs Market Value Share (%), By Drug Class, 2025

Figure 41: Rest of the World Fatty Liver Disease Drugs Market Value (USD million), By Route of Administration, 2025 & 2034

Figure 42: Rest of the World Fatty Liver Disease Drugs Market Value Share (%), By Route of Administration, 2025

Figure 43: Rest of the World Fatty Liver Disease Drugs Market Value (USD million), By Distribution Channel, 2025 & 2034

Figure 44: Rest of the World Fatty Liver Disease Drugs Market Value Share (%), By Distribution Channel, 2025

Figure 45: Global Fatty Liver Disease Drugs Market Share (%), by Company, 2025

List of Tables

Table 1: Global Fatty Liver Disease Drugs Market Revenue (USD million) Forecast, By Product, 2021-2034

Table 2: Global Fatty Liver Disease Drugs Market Revenue (USD million) Forecast, By Drug Class, 2021-2034

Table 3: Global Fatty Liver Disease Drugs Market Revenue (USD million) Forecast, By Route of Administration, 2021-2034

Table 4: Global Fatty Liver Disease Drugs Market Revenue (USD million) Forecast, By Distribution Channel, 2021-2034

Table 5: Global Fatty Liver Disease Drugs Market Revenue (USD million) Forecast, By Region, 2021-2034

Table 6: North America Fatty Liver Disease Drugs Market Revenue (USD million) Forecast, By Product, 2021-2034

Table 7: North America Fatty Liver Disease Drugs Market Revenue (USD million) Forecast, By Drug Class, 2021-2034

Table 8: North America Fatty Liver Disease Drugs Market Revenue (USD million) Forecast, By Route of Administration, 2021-2034

Table 9: North America Fatty Liver Disease Drugs Market Revenue (USD million) Forecast, By Distribution Channel, 2021-2034

Table 10: North America Fatty Liver Disease Drugs Market Revenue (USD million) Forecast, by Country, 2021-2034

Table 11: Europe Fatty Liver Disease Drugs Market Revenue (USD million) Forecast, By Product, 2021-2034

Table 12: Europe Fatty Liver Disease Drugs Market Revenue (USD million) Forecast, By Drug Class, 2021-2034

Table 13: Europe Fatty Liver Disease Drugs Market Revenue (USD million) Forecast, By Route of Administration, 2021-2034

Table 14: Europe Fatty Liver Disease Drugs Market Revenue (USD million) Forecast, By Distribution Channel, 2021-2034

Table 15: Europe Fatty Liver Disease Drugs Market Revenue (USD million) Forecast, by Country/ Sub-region, 2021-2034

Table 16: Asia Pacific Fatty Liver Disease Drugs Market Revenue (USD million) Forecast, By Product, 2021-2034

Table 17: Asia Pacific Fatty Liver Disease Drugs Market Revenue (USD million) Forecast, By Drug Class, 2021-2034

Table 18: Asia Pacific Fatty Liver Disease Drugs Market Revenue (USD million) Forecast, By Route of Administration, 2021-2034

Table 19: Asia Pacific Fatty Liver Disease Drugs Market Revenue (USD million) Forecast, By Distribution Channel, 2021-2034

Table 20: Asia Pacific Fatty Liver Disease Drugs Market Revenue (USD million) Forecast, by Country/ Sub-region, 2021-2034

Table 21: Rest of the World Fatty Liver Disease Drugs Market Revenue (USD million) Forecast, By Product, 2021-2034

Table 22: Rest of the World Fatty Liver Disease Drugs Market Revenue (USD million) Forecast, By Drug Class, 2021-2034

Table 23: Rest of the World Fatty Liver Disease Drugs Market Revenue (USD million) Forecast, By Route of Administration, 2021-2034

Table 24: Rest of the World Fatty Liver Disease Drugs Market Revenue (USD million) Forecast, By Distribution Channel, 2021-2034

STUDY PERIOD: 2021-2034
BASE YEAR: 2025
HISTORICAL DATA: 2021-2024
NO OF PAGES: 200

Buy Now

Download Free Sample

Security Code

Get 20% Free Customization

Expand Regional and Country Coverage, Segments Analysis, Company Profiles, Competitive Benchmarking, and End-user Insights.

Growth Advisory Services

Clients

Related Reports

Get In Touch With Us

US +1 833 909 2966 ( Toll Free )

UK +44 808 502 0280 ( Toll Free )

(APAC) +91 744 740 1245
sales@fortunebusinessinsights.com